NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
Clinical Trials
16 trialsNCT03506373 2026-03-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT03817320 2025-06-17
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Active not recruiting
NCT04047797 2025-04-20
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02924272 2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2 Completed
NCT03323151 2024-01-18
PrE0404
PrECOG, LLC.
Phase 1/2 Completed
NCT02898259 2022-09-26
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Case Comprehensive Cancer Center
Phase 1/2 Terminated
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT02169791 2021-09-02
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Northside Hospital, Inc.
Phase 2 Completed
NCT02400437 2020-09-02
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01953783 2020-08-26
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
Takeda
Phase 1 Completed
NCT01887587 2020-01-22
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
Medical College of Wisconsin
Phase 1 Terminated
NCT01939899 2019-10-29
Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
Takeda
Phase 2 Completed
NCT02158975 2017-11-13
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01454076 2017-11-01
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
Takeda
Phase 1 Completed
NCT00893464 2015-11-11
A Study of IXAZOMIB in Adult Patients With Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 1 Completed